MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-27-2026
Amneal Pharmaceuticals Total Non Current Liabilities 2011-2026 | AMRX
Annual Total Non Current Liabilities Amneal Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.79 B | 2.42 B | 2.56 B | 2.84 B | 2.88 B | 2.98 B | 2.77 B | 2.9 B | 1.42 B | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.98 B | 1.42 B | 2.62 B |
Quarterly Total Non Current Liabilities Amneal Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.78 B | 2.36 B | 2.35 B | 2.4 B | 2.4 B | 2.64 B | - | 2.74 B | 2.76 B | 2.84 B | 2.84 B | 2.86 B | 2.86 B | 2.88 B | 2.91 B | 2.95 B | 2.94 B | 2.97 B | 2.97 B | 2.97 B | 2.97 B | 2.77 B | 2.77 B | 2.77 B | 2.77 B | 2.9 B | 2.9 B | 2.9 B | 2.9 B | 1.42 B | 1.42 B | 1.42 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.97 B | 1.42 B | 2.66 B |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
165 M | $ 2.13 | -12.55 % | $ 219 M |  USA |
 |
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | USA |
 |
BioCardia
BCDA
|
1.3 M | $ 1.37 | 6.2 % | $ 29 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
7.69 M | $ 2.4 | -2.83 % | $ 132 M | USA |
 |
BioLineRx Ltd.
BLRX
|
8.22 M | $ 2.8 | -1.06 % | $ 908 M |  Israel |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
BioXcel Therapeutics
BTAI
|
1.4 M | $ 1.64 | -1.8 % | $ 4.16 M | USA |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
BeyondSpring
BYSI
|
37.6 M | $ 1.44 | 6.3 % | $ 58.1 M | USA |
 |
Cabaletta Bio
CABA
|
43.9 M | $ 3.34 | 0.6 % | $ 3.9 M | USA |
 |
AbCellera Biologics
ABCL
|
326 M | $ 3.7 | 2.49 % | $ 1.11 B |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Codexis
CDXS
|
28.2 M | $ 1.05 | 3.47 % | $ 77.1 M | USA |
 |
Cerus Corporation
CERS
|
58.1 M | $ 2.6 | 1.56 % | $ 480 M | USA |
 |
Certara
CERT
|
482 M | $ 7.17 | 1.27 % | $ 1.15 B | USA |
 |
Cullinan Management
CGEM
|
277 M | $ 15.91 | 2.65 % | $ 931 M | USA |
 |
Compugen Ltd.
CGEN
|
39.9 M | $ 2.28 | 25.97 % | $ 204 M | Israel |
 |
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | Canada |
 |
Coherus BioSciences
CHRS
|
189 M | $ 1.66 | -0.9 % | $ 156 M | USA |
 |
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
109 M | $ 3.88 | - | $ 116 M | France |
 |
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | USA |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Cocrystal Pharma
COCP
|
1.5 M | $ 1.02 | -0.97 % | $ 10.4 M | USA |
 |
Aptose Biosciences
APTO
|
10.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | USA |
 |
Collegium Pharmaceutical
COLL
|
17.1 M | $ 42.0 | 0.79 % | $ 1.33 B | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
2.29 M | $ 35.61 | -0.25 % | $ 3.7 B | USA |
 |
Athira Pharma
ATHA
|
876 K | - | - | $ 269 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
854 K | - | 17.91 % | $ 11.1 M | USA |